Loading news...
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of "Hold" by the eight analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the
Shares of Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) have received a consensus recommendation of "Hold" from the eight research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to
Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation November 12, 2025 10:00 AM EST Company Participants Jane Chung - CEO & Director Jonathan Fawcett Anthony Tolcher Hans-Peter Gerber - Chief Scientific Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Greetings.
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.59 per share a year ago.
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025.
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize the advancement of its three ADC programs and research and development collaborations.
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.59 per share a year ago.
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.